Nidlegy™ Phase III PIVOTAL Trial Meets the Study’s Primary Objective Demonstrating Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival for Patients with Locally Advanced Fully Resectable Melanoma

Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase [...]